Liver Transplant Rejection Clinical Trial
Official title:
A Clinical Pilot Study to Test the Acceptability and Feasibility of TruGraf Liver and TRAC Liver Testing as Part of Standard of Care: Optimizing Liver ImmunoSuppression (TRU-IMMUNO)
This is a prospective, multi-center, randomized study. The primary objective is to evaluate the feasibility and utility of TruGraf/TRAC Liver testing used in addition to standard of care measures of liver dysfunction to guide immunosuppression management.
This study will provide TruGraf Liver and TRAC liver tests to one group of transplant providers early after liver transplantation to clarify if the Trugraf Liver and TRAC Liver results can complement their immunosuppression minimization strategies to avoid complications and reduce the occurrence of acute rejection. The ability to decrease IS will be compared to the group that does not receive the test results. Subjects will be randomized into 2 groups: one will receive Trugraf/TRAC Liver testing and the other will not. Subjects in the biomarker arm will have TruGraf Liver and TRAC Liver testing at study enrollment (1-2 months post-liver transplant) and thereafter every month for 6 months. Subjects will also have Trugraf Liver and TRAC Liver testing at months 9 and 12 following transplantation (7-8 and 10-11 months post baseline). The TruGraf and TRAC Liver results will be used in the biomarker arm in conjunction with all other clinical parameters available to guide decisions related to immunosuppression changes. There are no protocol mandated immunosuppression changes. Subjects in the standard of care arm will not have biomarkers available for decisions related to immunosuppression changes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01678937 -
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents
|
N/A | |
| Completed |
NCT03781414 -
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
|
Phase 2 | |
| Recruiting |
NCT02260375 -
MSC Therapy in Liver Transplantation
|
Phase 1 | |
| Not yet recruiting |
NCT04514666 -
VOCs in Kidney and Liver Transplants
|
N/A | |
| Completed |
NCT01745731 -
Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration
|
Phase 2 | |
| Enrolling by invitation |
NCT05082077 -
Global Utilization And Registry Database for Improved preservAtion of doNor Livers
|
||
| Completed |
NCT06060808 -
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.
|
||
| Completed |
NCT03874286 -
The TOGETHER Project - Liver
|
||
| Completed |
NCT04789213 -
Mortality, Morbidity and Risk Factors of Liver Retransplantation
|
||
| Recruiting |
NCT06400771 -
Safety of DNP007 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT03603548 -
Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial
|
N/A | |
| Withdrawn |
NCT03315052 -
Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
|
Phase 4 | |
| Enrolling by invitation |
NCT05655273 -
Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients
|
Phase 4 | |
| Active, not recruiting |
NCT05325073 -
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
|
Phase 4 | |
| Recruiting |
NCT05707520 -
Long-term Benefit of MPA in Liver Transplantation
|
||
| Recruiting |
NCT04657562 -
The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma
|
||
| Completed |
NCT01444079 -
Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation
|
N/A | |
| Active, not recruiting |
NCT06153641 -
Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients
|